Roivant Sciences (ROIV) Non-Current Assets (2021 - 2026)
Roivant Sciences' (ROIV) quarterly Non-Current Assets came in at $153000.0 in Q1 2026, down 24.26% YoY from $202000.0 in Q1 2025, and down 100.0% on a QoQ basis from $4.3 billion in Q4 2025.
Roivant Sciences (ROIV) Non-Current Assets (2021 - 2026) Analysis & Trends
Roivant Sciences (ROIV) has 6 years of Non-Current Assets data on file, last reported at $153000.0 in Q1 2026.
- Quarterly Non-Current Assets fell 24.26% year-over-year to $153000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $153000.0 (down 24.26% YoY) and the FY2026 annual result came in at $153000.0, down 24.26% from the prior year.
- Non-Current Assets slipped to $153000.0 in Q1 2026, from $4.3 billion in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $4.3 billion in Q4 2025 to a low of $153000.0 in Q1 2026.
- A 5-year average of $837.3 million and a median of $513.9 million in 2023 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2023 — Non-Current Assets soared 257.11% — and 2025, when it sank 98.6%.
- Tracing ROIV's Non-Current Assets over 5 years: stood at $556.7 million in 2022, then soared by 257.11% to $2.0 billion in 2023, then increased by 17.73% to $2.3 billion in 2024, then surged by 83.05% to $4.3 billion in 2025, then plunged by 100.0% to $153000.0 in 2026.
- The last three Non-Current Assets figures came in at $153000.0 (Q1 2026), $4.3 billion (Q4 2025), and $551.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 564.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 564.41 Mn |
| Mar 31, 2026 | 153,000.00 |
| Dec 31, 2025 | 4.28 Bn |
| Sep 30, 2025 | 550.95 Mn |
| Jun 30, 2025 | 416.85 Mn |
| Mar 31, 2025 | 202,000.00 |
| Dec 31, 2024 | 2.34 Bn |
| Sep 30, 2024 | 404.91 Mn |
| Jun 30, 2024 | 494.95 Mn |
| Mar 31, 2024 | 14.42 Mn |
| Dec 31, 2023 | 1.99 Bn |
| Sep 30, 2023 | 513.92 Mn |
| Jun 30, 2023 | 575.49 Mn |
| Mar 31, 2023 | 591.02 Mn |
| Dec 31, 2022 | 556.73 Mn |
| Sep 30, 2022 | 500.67 Mn |
| Jun 30, 2022 | 560.96 Mn |
| Mar 31, 2022 | 438.61 Mn |
| Dec 31, 2021 | 511.84 Mn |
| Sep 30, 2021 | 547.15 Mn |